» Articles » PMID: 6323316

Use of a Purified Outer Membrane Protein F (porin) Preparation of Pseudomonas Aeruginosa As a Protective Vaccine in Mice

Overview
Journal Infect Immun
Date 1984 Apr 1
PMID 6323316
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

The outer membrane protein F (porin) from the PAO1 strain of Pseudomonas aeruginosa was purified by two different methods. One procedure involved separation by column chromatography of proteins extracted from isolated outer membranes, whereas the other involved extraction from gels after slab polyacrylamide gel electrophoresis of proteins extracted from cell envelopes. Both procedures yielded protein F preparations which successfully immunized mice from subsequent challenge with the PAO1 strain. The protein F preparations contained small quantities of lipopolysaccharide (LPS). This level of LPS contamination protected immunized mice from challenge with the homologous LPS serotype strain. However, immunization of mice with protein F preparations from the PAO1 strain also afforded protection against challenge with two different LPS serotype strains. This protective ability was lost when the protein F preparation was treated with papain before use as a vaccine. These observations support the conclusion that protein F has protective ability, which is not due to LPS contamination, when given as a vaccine. After immunization with the protein F preparation, mice showed an increase in antibody titer to the purified protein F preparation by enzyme-linked immunosorbent assay. Mice were protected passively by administration of rabbit antisera raised to the protein F preparation. These results indicate that the protein F preparation elicits a specific humoral antibody response in immunized animals. Our results suggest that purified protein F has potential as an effective vaccine for P. aeruginosa.

Citing Articles

Understanding -Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Sainz-Mejias M, Jurado-Martin I, McClean S Cells. 2020; 9(12).

PMID: 33291484 PMC: 7762141. DOI: 10.3390/cells9122617.


Chronic Infection by Mucoid Pseudomonas aeruginosa Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F.

Quigley K, Reynolds C, Goudet A, Raynsford E, Sergeant R, Quigley A Am J Respir Crit Care Med. 2015; 191(11):1250-64.

PMID: 25789411 PMC: 4476516. DOI: 10.1164/rccm.201411-1995OC.


Vaccines for Pseudomonas aeruginosa: a long and winding road.

Priebe G, Goldberg J Expert Rev Vaccines. 2014; 13(4):507-19.

PMID: 24575895 PMC: 4521563. DOI: 10.1586/14760584.2014.890053.


Immunoproteomics: the key to discovery of new vaccine antigens against bacterial respiratory infections.

Dennehy R, McClean S Curr Protein Pept Sci. 2013; 13(8):807-15.

PMID: 23305366 PMC: 3594738. DOI: 10.2174/138920312804871184.


Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization.

Peluso L, de Luca C, Bozza S, Leonardi A, Giovannini G, Lavorgna A BMC Microbiol. 2010; 10:9.

PMID: 20070893 PMC: 2820439. DOI: 10.1186/1471-2180-10-9.


References
1.
Droge W, Lehmann V, LUDERITZ O, Westphal O . Structural investigations on the 2-keto-3-deoxyoctonate region of lipopolysaccharides. Eur J Biochem. 1970; 14(1):175-84. DOI: 10.1111/j.1432-1033.1970.tb00276.x. View

2.
Whitecar Jr J, Luna M, Bodey G . Pseudomonas bacteremia in patients with malignant diseases. Am J Med Sci. 1970; 60(4):216-23. DOI: 10.1097/00000441-197010000-00003. View

3.
Nathan P, Holder I, MacMILLAN B . Burn wounds: microbiology, local host defenses, and current therapy. CRC Crit Rev Clin Lab Sci. 1973; 4(1):61-100. DOI: 10.3109/10408367309151684. View

4.
Gilleland Jr H, Murray R . Ultrastructural study of polymyxin-resistant isolates of Pseudomonas aeruginosa. J Bacteriol. 1976; 125(1):267-81. PMC: 233360. DOI: 10.1128/jb.125.1.267-281.1976. View

5.
Holby N, Olling S . Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases. Acta Pathol Microbiol Scand C. 1977; 85(2):107-14. View